देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
PERINDOPRIL ERBUMINE
APOTEX INC
C09AA04
PERINDOPRIL
2MG
TABLET
PERINDOPRIL ERBUMINE 2MG
ORAL
15G/50G
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0127178001; AHFS:
APPROVED
2018-03-07
_APO-PERINDOPRIL (Perindopril erbumine tablets) _ _Page 1 of 75_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr APO-PERINDOPRIL Perindopril erbumine tablets Tablets, 2 mg, 4 mg and 8 mg, Oral Apotex Standard Angiotensin Converting Enzyme Inhibitor Submission Control Number: 272361 APOTEX INC. 150 Signet Drive Weston, Ontario M9L 1T9 Date of Initial Authorization: MAR 07, 2018 Date of Revision: AUG 01, 2023 _APO-PERINDOPRIL (Perindopril erbumine tablets) _ _Page 2 of 75_ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 08/2023 7 WARNING AND PRECAUTIONS 08/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS ........................................................................................................... 4 1.1 Pediatrics (< 18 years of age) ............................................................................. 4 1.2 Geriatrics (>65 years of age) ............................................................................... 4 2 CONTRAINDICATIONS ............................................................................................... 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .......................................................... 5 4 DOSAGE AND ADMINISTRATION............................................................................... 5 4.1 Dosing Considerations ........................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment ................................................... 6 4.4 Administration ................................................................................ पूरा दस्तावेज़ पढ़ें